Antibody

Abstract

Provided is an active ingredient of a pharmaceutical composition for treating myeloma. Specifically, provided is an antibody whose epitope is present in the region of the amino acid residue positions 20 to 109 of human integrin β7.

1 - 15 . (canceled) 
     
     
         16 . A chimeric antigen receptor, comprising an anti-integrin β 7  scFv, wherein the anti-integrin β 7  scFv comprises:
 a heavy chain variable region comprising an amino acid sequence having at least 80% identity with the amino acid sequence of SEQ ID NO: 4, and 
 a light chain variable region comprising an amino acid sequence having at least 90% identity with the amino acid sequence of SEQ ID NO: 9. 
 
     
     
         17 . The chimeric antigen receptor of  claim 16 , wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 1, the amino acid sequence of SEQ ID NO: 2, and the amino acid sequence of SEQ ID NO: 3, and
 wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO: 6, the amino acid sequence of SEQ ID NO: 7, and the amino acid sequence of SEQ ID NO: 8.   
     
     
         18 . The chimeric antigen receptor of  claim 16 , which binds to a region of amino acid residue positions 20 to 90 of an anti-integrin β 7 . 
     
     
         19 . The chimeric antigen receptor of  claim 16 , which is multispecific. 
     
     
         20 . A cell comprising the chimeric antigen receptor of  claim 16 . 
     
     
         21 . The cell according to  claim 20 , which is a chimeric antigen receptor T-cell or NK-cell. 
     
     
         22 . A pharmaceutical composition comprising the cell according to  claim 20 . 
     
     
         23 . A method of treating multiple myeloma comprising administering the cell of  claim 20  to a patient in need thereof. 
     
     
         24 . A pharmaceutical composition comprising a dose from 10 4  cells/kg to 10 9  cells/kg of the cell according to  claim 20 .